Sign In
Last checked at 
17 Mar 2021 07:00
LEI: 549300Q7EXQQH6KF7Z84
17 MARCH 2021
RTW Venture Fund Limited
(the "Company")
ISSUE OF EQUITY
On 16 March 2021, the Company issued 5,133,319 new ordinary shares of no par value each at a price of US$2.22 per share; these shares rank pari passu with the existing ordinary shares in issue. The issue price equates to a premium to the net asset value per share at the time of the transaction.
As a result of this issue, the total number of ordinary shares in issue now stands at 204,047,167 and the total number of voting rights in the Company is 204,047,167. There are no shares held in treasury.
The above figure of 204,047,167 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company confirms that application for admission will be made to London Stock Exchange plc and it is expected that admission will occur at 8:00 a.m. on 22 March 2021.
For further information, please contact:
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225-8885
J.P. Morgan Cazenove +44 (0) 20 7742 4000
William Simmonds
James Bouverat (Sales)
Barclays +44 (0) 20 7623 2323
Tom Swerling
Andrew Tusa
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Follow the stocks
